The PSI is a self-administered patient-reported outcome measure (PRO) intended for use in assessing symptom severity in chronic plaque psoriasis. It has been developed in accordance with FDA Guidelines for Content Validity and Instrument Performance. It has been used in multiple clinical trials and has supported one label claim with the FDA.

Continue scrolling to find out more about:

  • Obtaining a license to use the PSI
  • Versions available
  • Translations available
  • Resources and references